ixlayer is Recognized as a Premiere Patient Engagement Startup and Named to the 2025 New York Digital Health 100
ixlayer is a top 100 healthcare company powering direct-to-patient platforms for biopharma
NEW YORK, NY/February 6, 2025 – ixlayer, the leading direct-to-patient platform built for biopharma, has announced that it has been named to the New York Digital Health 100 (DH100), released today by Digital Health New York (DHNY). Joining the ranks of past winners Capsule, Maven, Oscar, Ro, Sword, Talkiatry, Talkspace and ZocDoc, ixlayer was selected for its strength of leadership, funding, revenue, market fit and differentiated offerings.
To see how ixlayer is transforming the patient experience for biopharma, visit ixlayer.com.
This recognition comes from DHNY, an organization founded in collaboration with AlleyCorp to reinforce New York City’s leadership in healthcare innovation and the companies driving the future of healthcare. The DH100 is their annual list celebrating groundbreaking and influential startups in New York.
“Being named to the DH100 is a testament to ixlayer’s commitment to transforming healthcare by reducing barriers and burdens for patients, improving access to care and making pharma marketing way more actionable,” said Pouria Sanae, co-founder and CEO of ixlayer. “Our team at ixlayer is pleased and proud to be recognized and will continue our work driving the future of accessible, patient-centered care.”
“The New York Digital Health 100 continues to evolve in its sixth year as we welcome 48 new startups including ixlayer,” said Bunny Ellerin, co-founder and CEO, DHNY. “This is an exceptional class of innovators tackling healthcare’s most pressing challenges.”
About ixlayer
ixlayer [pronounced: I-X-layer] is the leading provider of cloud-based platforms that power a seamless, end-to-end direct-to-patient healthcare experience. The name reflects our core strengths: “i” for robust data and technology infrastructure and “x” for exceptional user experience. ixEngage by ixlayer seamlessly integrates with all healthcare ecosystem partners, connecting biopharma with patients in a user-centric way. This proprietary technology accelerates the path to diagnoses, supports optimal care, drives operational efficiency, and improves health equity and outcomes for all. To date, ixlayer has activated over four million patient care journeys across more than 1,100 programs, simplifying the complex web of healthcare. Learn more at www.ixlayer.com.
About Digital Health New York (DHNY)
Digital Health New York (DHNY) is a connected community of digital health leaders who share ideas, spark new directions and create success across the entire ecosystem. As an organization, we seek to increase the visibility of New York City as a leader in healthcare innovation and showcase the companies and leaders creating the future of healthcare. Our flagship event, DHNY Summit, brings together an elite group of entrepreneurs, investors, payers, providers and executives to cultivate the New York digital health community and drive impactful conversations around the current and future state of digital health. DHNY was founded in 2022 in collaboration with AlleyCorp. For more information or to join DHNY’s mailing list, please visit www.dhny.co.
DH100 Methodology
To compile the DH100, we invited companies to complete an in-depth application with both quantitative and qualitative measures to help us get to know the company better. We also used our dynamic database of digital health companies in the region to round out the consideration set. A company qualified for consideration if it maintained headquarters or employed at least 5 people in the New York region. Companies that were public or non-profit; founded before 2014; or had an exit were excluded. We evaluated companies on a number of factors, including but not limited to: strength of application, leadership, number of employees, funding, revenue, market fit, differentiated offerings, and community engagement.
MEDIA CONTACT:
Jennifer Perciballi
Oak+Cannon PR for ixlayer
jennifer@oakandcannon.com
About ixlayer
ixlayer is the only end-to-end, direct-to-patient platform built for biopharma and optimized for patient choice. We help biopharma companies connect with patients from testing to treatment with speed, transparency, control and impact.
